Active material: Doksazozin
When ATH: C02CA04
CCF: Alpha1-adrenoblokator. Antihypertensive drugs. Preparation, used in violation of urination in benign prostate hyperplasia glands
ICD-10 codes (testimony): I10, N40
When CSF: 01.01.02.02
Manufacturer: KRKA d.d. (Slovenia)
Pills white, round, slightly biconcave, with beveled edges.
| 1 tab. | |
| doxazosin mesylate | 1.21 mg |
| that corresponds to the content of doxazosin | 1 mg |
Excipients: microcrystalline cellulose, sodium starch glycolate, magnesium stearate, sodium lauryl, lactose monohydrate.
10 PC. – упаковки ячейковые контурные (2) – пачки картонные.
10 PC. – упаковки ячейковые контурные (3) – пачки картонные.
Pills white, round, flat, with beveled edges and a notch (Valium) on one side.
| 1 tab. | |
| doxazosin mesylate | 2.43 mg, |
| that corresponds to the content of doxazosin | 2 mg |
Excipients: microcrystalline cellulose, sodium starch glycolate, magnesium stearate, sodium lauryl, lactose monohydrate.
10 PC. – упаковки ячейковые контурные (2) – пачки картонные.
10 PC. – упаковки ячейковые контурные (3) – пачки картонные.
Pills white, round, flat, with beveled edges and a notch (Valium) on one side.
| 1 tab. | |
| doxazosin mesylate | 4.86 mg, |
| that corresponds to the content of doxazosin | 4 mg |
Excipients: microcrystalline cellulose, sodium starch glycolate, magnesium stearate, sodium lauryl, lactose monohydrate.
10 PC. – упаковки ячейковые контурные (2) – пачки картонные.
10 PC. – упаковки ячейковые контурные (3) – пачки картонные.
Selective antagonist of α1-adrenoreceptorov. It was the expansion of peripheral blood vessels, which leads to a decrease in peripheral vascular resistance and reduction in blood pressure. Effect of the drug on cardiac function and is marginally transitory nature. Doxazosin lowers total cholesterol, LDL-C and triglycerides, increases HDL-cholesterol content in blood serum. Thus, drug helps prevent the development of atherosclerosis and coronary heart disease. Doxazosin has a neutral or normalizing effect on insulin and blood glucose, so the product can be used in patients with diabetes. It inhibits platelet aggregation. In long-term treatment of doxazosin reduces the mass of the left ventricle.
Doxazosin prevents the smooth muscle of the upper urethra and the muscles of the prostate, that surround the urethra. Relaxation of these muscles leads to relief of urination, which significantly reduces the unpleasant symptoms, observed in benign prostatic hyperplasia. The therapeutic effect is within the first 2 weeks of treatment and increases with subsequent therapy. Action doxazosin on normal blood pressure slightly.
Camiri can be used in patients with renal insufficiency, chronic obstructive pulmonary disease, peripheral arterial disease, and gout.
In single dose duration of Camiri 24 no. Action on blood pressure is most pronounced for 2-6 h after dosing. The maximum effect is achieved after a few weeks of regular reception. If the therapeutic effect is not enough, patients can be prescribed other antihypertensive agents: beta-blockers, Diuretic, calcium channel blockers and ACE inhibitors.
Absorption
After oral administration, doxazosin is well absorbed from the gastrointestinal tract. Cmax achieved through 1.5-3 no.
Distribution
Doxazosin is almost completely bound to plasma proteins.
Metabolism
It is metabolized in the liver.
Deduction
T1/2 is 16-22 no.
Excreted in the feces as metabolites. Less 10% the dose is excreted in the urine.
- The treatment of mild to moderate hypertension (as monotherapy or in combination with other antihypertensive drugs);
- Symptomatic treatment of benign prostatic hyperplasia.
Set individually and adjusted depending on the effectiveness of treatment and / or development of side effects.
At hypertension initial dose of doxazosin is 1 mg / day. The first dose should be taken at night before bedtime. Depending on the effect of the drug on blood pressure, dose can be gradually increased at intervals of 1-2 weeks before 2 mg, 4 mg, 8 mg 1 time / day. Usually, average daily doses ranging from 2 mg 8 mg. The maximum daily dose is 16 mg.
At benign prostatic hyperplasia in patients with normal blood pressure starting dose is 1 mg / day. The first dose should be taken at night before bedtime. Depending on the response to treatment, dose can be gradually increased at intervals of 1-2 weeks before 2 mg, 4 mg, 8 mg 1 time / day. The average daily dose is from 2 mg 4 mg. The maximum daily dose - 8 mg.
At benign prostatic hyperplasia in patients with hypertension drug administered in the same doses, as only patients with hypertension.
In Patients with liver failure the drug is used at lower doses (due to slow metabolism doxazosin).
The drug can be taken before, during or after meals.
If the drug at the usual time passed, it should be as soon as possible to take this dose. If it is time for the next dose, you should only take it, not doubling the dose. It is important to take the drug regularly. If the patient is taking the drug for several days, the new therapeutic course should start with the lowest dose.
Cardio-vascular system: at the beginning of treatment and with increasing doses of the drug may be a tendency to fainting (especially when changing from a lying or sitting position to a standing position), dizziness, headache. These effects disappear on their own, but if they are severe or persist for a long time, the dose should be reduced or stop taking the drug; in some cases, possible tachycardia, palpitations.
Rarely (connection with the reception of doxazosin is not clearly established) – усугубление стенокардии, myocardial infarction, cerebrovascular stroke, abnormal heart rhythm.
From the central and peripheral nervous system: You may be feeling tired, drowsiness, muscular weakness.
From the digestive system:
possible nausea; редко – нарушения показателей функции печени, cholestasis, hepatitis.The respiratory system: possible bronchitis, breathlessness, a feeling of nasal congestion, nasal discharge.
From the blood coagulation system: a rare - thrombocytopenia, purpura, nosebleeds.
From the urinary system: редко – гематурия; в отдельных случаях – недержание мочи.
Other: possible swelling of the ankles and legs, flu-like symptoms; редко – кожная сыпь; in a few cases (connection with the reception of doxazosin is not clearly established) – импотенция.
- Obstruction of the digestive tract or esophagus;
- Narrowing of the gastrointestinal tract of any;
- Children's age;
- Hypersensitivity to doxazosin and other ingredients;
- Increased sensitivity to other quinazoline derivatives (prazosin, terazosin).
Camiri Application during pregnancy is possible only for health reasons, when the expected benefit of therapy for the mother outweighs the potential risk to the fetus.
If necessary, use during lactation should stop breastfeeding, tk. Camiri safety in infants is not installed.
Doxazosin has no effect on the concentration of PSA (Prostate specific antigen).
Upon receipt of Camiri, especially the first dose, possible orthostatic hypotension (fainting). To avoid such phenomena, treatment should be initiated with a dose 1 mg in the evening before going to bed. The dosage should be gradually increased at intervals of 1-2 of the week. Patients should be warned of the possibility of orthostatic hypotension and Share gently rising from a lying or sitting position. This is especially true for the elderly and the sick, simultaneously receiving other antihypertensive drugs or diuretics. To use caution in combination with other antihypertensive agents, especially at the beginning of treatment, tk. may increase the antihypertensive effect.
Doxazosin is not recommended in patients with arterial hypertension. Before therapy for patients with symptoms, caused by benign prostatic hyperplasia, necessary to urological examination.
Patients with hepatic insufficiency doxazosin is metabolized more slowly, therefore increasing the dose of the drug should be made with caution.
Use in Pediatrics
Safety and effectiveness in pediatric patients has not been established, and the drug is not recommended for children.
Effects on ability to drive vehicles and management mechanisms
At the beginning of treatment and when changing Kamirenom dose possible excessive reduction of blood pressure, which may be accompanied by dizziness. Therefore, in such cases, it is not recommended to drive and engage in potentially hazardous activities.
Symptoms: Excessive hypotension, dizziness, possible fainting.
Treatment: In most cases, it dose reduction or temporary interruption of therapy. The patient should be given the supine position with a low headboard and legs slightly raised. Do not induce vomiting. For removing unabsorbed drug from the gastrointestinal tract should be performed gastric lavage, assign activated carbon, laxative. Назначают агонисты a-адренорецепторов (eg, noradrenaline). Hemodialysis nyeeffyektivyen (as doxazosin almost completely bound to plasma proteins).
With simultaneous use of Camiri with other antihypertensive agents (блокаторами b-адренорецепторов, Diuretics, calcium channel blockers, ACE inhibitors) there is a growing anti-hypertensive effect (the use of such a combination is possible, However, caution should be exercised, especially at the beginning of treatment).
With simultaneous use of Camiri with nitrates, anesthetics, tricyclic antidepressants, and ethanol may enhance the antihypertensive effect (the use of such a combination is possible, However, caution should be exercised, especially at the beginning of treatment).
In an application with drugs Camiri, It affects the rate of metabolism in the liver, possibly slowing or accelerating metabolic doxazosin (should be used with caution).
The drug is released under the prescription.
The drug should be stored at a temperature no higher than 30 ° C. Shelf life - 3 year.
This site uses cookies and services to collect technical data from visitors to ensure performance and improve the quality of service.. By continuing to use our site, you automatically agree to the use of these technologies.
Read More